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Abstract 
In the present study, the effects of an intracerebroventricular (i.c.v.) dose of histamine (0.1, 1.0 or 10.0 /xg) on the hippocampal 
somatostatin (SS) receptor/effector system in Wistar rats were investigated. In view of the rapid onset of histamine action, the effects of 
histamine on the somatostatinergic system were studied 2 h after its administration. Hippocampal SS-like immunoreactivity (SSLI) levels 
were not modified by any of the histamine doses studied. SS-mediated inhibition of basal and forskolin (FK)-stimulated adenylyi cyclase 
(AC) activity was markedly increased in hippocampal membranes from rats treated with 10 tzg of histamine (23% + 1% vs. 17% + 1% 
and 37% -i- 2% vs. 23% + 1%, respectively). In contrast, neither the basal nor the FK-stimulated enzyme activities were affected by 
histamine administration. The functional activity of the hippocampal guanine-nucleotide binding inhibitory protein (G i protein), as 
assessed by the capacity of the stable GTP analogue 5'-guanylylimidodiphosphate (Gpp{NH]p) to inhibit FK-stimulated AC activity, was 
not modified by histamine administration. These data suggest hat the increased response of the enzyme to SS was not related to an 
increased functional activity of G i proteins. In fact, the increased AC response to SS in hiPpocampal membranes from histamine (10 
/zg)-treated rats was associated with quantitative changes in the SS receptors. Equilibrium binding data obtained with [12~I]Tyr~-SS 
indicate an increase in the number of specific SS receptors (541 + 24 vs. 365 + 16 fmol/mg protein, P < 0.001) together with a decrease 
in their apparent affinity (0.57 + 0.04 vs. 0.41 + 0.03 nM, P < 0.05) in rat hippocampai membranes from histamine (10 /xg)-treated rats 
as compared to control animals. With the aim of determining if these changes were related to histamine binding to its specific receptor 
sites, the histaminergic H1 and H 2 receptor antagonists mepyramine and cimetidine, respectively, were administered 1 h before histamine 
injection. The pretreatment with mepyramine or cimetidine induced an increase in the number and affinity constant of the SS receptors 
whereas the simultaneous pretreatment with both histamine antagonists prevented the histamine-induced changes in SS binding to its 
receptors. Since the hippocampal SS receptor/effector system is modulated by histamine, it is tempting to speculate that in the 
hippocampus, SS could be involved as a mediator of the histamine ffects on behaviors uch as learning and memory. 
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1. Introduction 
Somatostatin (SS) is a neuropeptide widely distributed 
in the brain [11]. In the hippocampus, immunohistochemi- 
cal studies have revealed many SS-containing interneurons 
and a profuse network of intrinsic and extrinsic SS-con- 
taining fibers that appear to project to pyramidal and 
granule neurons [3,18]. Specific SS receptors are present in 
the hippocampus [39], suggesting that SS may be a neuro- 
transmitter or neuromodulator in this brain area. Biochemi- 
cal analysis demonstrated that SS receptors are coupled to 
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GTP-binding proteins (G-proteins) [22]. The G-proteins 
then couple the SS receptors with multiple effector pro- 
teins to either inhibit them, as occurs with adenylyl cyclase 
(AC) [44] and voltage-dependent Ca 2÷ channels [52], or to 
activate them, as occurs with different K ÷ channels [51]. 
Several findings suggest an important role for SS in cogni- 
tive processes uch as learning and memory by modulating 
neuronal activity in the hippocampus [2,16]. Recently, it 
has been shown that SMS 201-995, a specific peptidase-re- 
sistant SS analog, has anticonvulsant activity on EEG 
seizures induced by glutamate analogs in the hippocampus 
[50], thus suggesting an inhibitory role of hippocampal SS 
on seizures. 
There are data supporting the hypothesis that the so- 
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matostatinergic and histaminergic systems are interrelated 
and that reciprocal regulation occurs. Centrally adminis- 
tered SS produces a dose-related ecrease in histamine 
levels in the rat hippocampus [7]. Ample evidence xists 
for histaminergic projections to the hippocampus [33,53], a 
brain area rich in SS content and receptors [21,40]. These 
and other subcortical afferents could play a decisive role in 
the expression of long-term potentiation. Furthermore, sev- 
eral studies uggest that the histamine H 1 and H 2 receptors 
may mediate together the actions of histamine in the 
hippocampus [46]. SS and histamine participate in a simi- 
lar manner in the regulation of a number of behaviors, 
including those subserving memory and learning 
[2,16,19,46,49] and motor activity [11,46]. It has been 
suggested that SS [24] and histamine [43] may act as 
endogenous anticonvulsants in the hippocampus. In view 
of all the above, the aim of this study was to elucidate the 
role of histamine in modulating the SS receptor/cffector 
system in the rat hippocampus. Since it appears that SS 
modulation of neuronal function involves the inhibition of 
AC activity by the occupation of receptor sites negatively 
coupled, via G-proteins, to this enzyme [32], we have 
assessed the integrity of SS receptor function by assaying 
both the levels of receptor ecognition sites and the ability 
of SS to inhibit AC activity. In addition, we assessed the 
functional activity of the guanine nucleotide-binding in- 
hibitory protein (G~) and determined the effect of his- 
tamine on SS-like immunoreactivity (SSLI) content in the 
hippocampus. The effects of pretreatment with the his- 
tamine H~ and H 2 receptor antagonists mepyramine and 
cimetidine, respectively, on the above-cited parameters 
were also evaluated. 
C-terminal cysteine residue is required for antibody bind- 
ing, suggesting that the antigen site is directed towards the 
central part of the molecule containing the tryptophan 
residue. The binding of SS-14 to this antibody does not 
depend on an intact disulfide bond in the molecule as 
breaking of the disulfide bond by reaction with (I. 1% 
mercaptoethanol (boiling water bath, 5 min) did not change 
the immunoreactivity of the peptide. 
2.2. Experimental nimals 
The animals used in this study were Wistar rats ( n = 6(1) 
weighing between 200 and 250 g. Rats were maintained on 
a 12 h light/dark cycle (07.00-19.00) and allowed free 
access to food. Histamine was dissolved in 0.9% NaCl and 
administered intracerebroventricularly (i.c.v.) in a volume 
of l0/zl  according to the method escribed by Noble et al. 
[27] at a dose of 0.1, 1.0 or 10.0 /xg of free base, as 
previously described [41]. Mepyramine (30 mg/kg) [28] 
was dissolved in saline and cimetidinc (20 p,g/rat) [26] 
was first dissolved in dimethyl sulfoxide and then diluted 
with saline to the concentration required. Mepyramine 
and/or cimetidine were administered via an intraperitoneal 
(i.p.) and i.c.v, injection, respectively, 1 h before histamine 
administration. In all experiments, control animals re- 
ceived equivalent volumes of the corresponding vehicle. 
Rats were killed by decapitation 2 h after the last drug 
injection. The brain was rapidly removed and the hip- 
pocampus was dissected over ice according to the method 
of Glowinski and Iversen [14]. 
2.3. Tissue extraction and SS radioimmunoassay 
2. Materials and methods 
2.1. Chemicals 
Synthetic Tyrt~-SS and SS-14 were purchased from 
Universal Biologicals Ltd (Cambridge, U.K.): carrier-free 
Na12Sl (IMS 30. 100 mCi/ml) and rabbit antibody were 
purchased from the Radiochemical (?entre (Amersham, 
UK); histamine hydrochloride, mepyramine maleate, cime- 
tidine, bacitracin, bovine serum albumin (BSA), forskolin 
(FK), phenylmethylsulfonyl fluoride (PMSF), 3-isobutyl- 
1-methylxanthine (IBMX), GTP and Gpp[NH]p were sup- 
plied by Sigma Quimica (Madrid, Spain). The rabbit anti- 
body used in the radioimmunoassay technique was pur- 
chased from the Radiochemical Centre (Amersham, UK). 
This antiserum was raised in rabbits against SS-14 conju- 
gated to BSA and is specific for SS, but since SS-14 
constitutes the C-terminal portions of both SS-25 and 
SS-28, the antiserum does not distinguish between these 
three forms. Cross-reactivity with other peptides was less 
than 0.5%. Cross-reaction with several SS analogues 
demonstrated that neither the N-terminal glycine nor the 
For SSLI measurements, he hippocampus was rapidly 
homogenized in 1 ml 2 M acetic acid using a Brinkman 
polytron (setting 5, 30 s). The extracts were boiled for 5 
min in a water bath, chilled in ice, and aliquots (100 /a,l) 
were removed for protein determination [34]. The ho- 
mogenates were subsequently centrifuged at 15000 × g 
for 15 min at 4°C and the supernatant was neutralized with 
2 M NaOH. The extracts were then stored at -70°C until 
assay. The SSLI content was determined in tissue extracts 
by a modified radioimmunoassay method [34], with a 
sensitivity limit of 10 pg/ml. Incubation tubes prepared in 
duplicate contained 1011 p,I samples of unknown or stan- 
dard solutions of 0-500 pg cyclic SS tetradecapeptide 
diluted in phosphate buffer (0.05 M, pH 7.2 containing 
I).3% BSA, 0.01 M EDTA), 200 /xl of appropriately 
diluted anti-SS serum, 100 /xl of freshly prepared 
[Iz~I]Tyr11-SS diluted in buffer to give 6000 cpm/assay 
tube (equivalent to 5-10 pg), and enough buffer to give a 
final volume of 0.8 ml. All reagents, as well as the assay 
tubes, were kept chilled in ice before their incubation for 
48 h at 4°C. Separation of bound and free hormone was 
accomplished by the addition of 1 ml dextran-coated char- 
coal (dextran T-70: (I.2% w/v ,  Pharmacia, Uppsala, Swe- 
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den; charcoal Norit A: 2% w/v ,  Serva Feinbiochemica, 
Heidelberg, Germany). Serial dilution curves for the hip- 
pocampus were parallel to the standard curve. The intra- 
and inter-assay variation coefficients were 6.2 and 8.6%, 
respectively. 
2.4. Binding assay 
Tyr1~-SS was radioiodinated by chloramine-T iodina- 
tion according to the method of Greenwood [15]. The 
tracer was purified in a Sephadex G-25 fine column (1 × 
100 cm) equilibrated with 0.1 M acetic acid containing 
BSA 0.1% (w/v). The specific activity of the purified 
labelled peptide was about 600 Ci/mmol. ~ 
Hippocampal membranes were prepared as previously 
described by Reubi et al. [37]. Protein concentration was 
assayed by the method of Lowry et al. [23], with BSA as a 
standard. Specific SS binding was measured according to 
the modified method of Czernik and Petrack [8]. Briefly, 
the membranes (0.15 mg protein/ml) were incubated in 
250 /xl of a medium containing 50 mM Tris-HCl buffer 
(pH 7.5), 5 mM MgCI 2, 0.2% (w/v)  BSA and 0.1 mg/ml 
bacitracin with 250 pM [~25 i]Tyr ~ ~-SS either in the absence 
or presence of 0.01-10 nM unlabelled SS. After a 60 min 
incubation at 30°C, bound and free ligand were separated 
by centrifugation at 11 000 × g for 2 min and the radioac- 
tivity in the resultant pellet was measured. Nonspecific 
binding was obtained from the amount of radioactivity 
bound in the presence of 10 -7  M SS and represented 
about 20% of the binding observed in the absence of 
unlabelled peptide. This nonspecific omponent was sub- 
tracted from the total bound radioactivity in order to obtain 
the corresponding specific binding. 
2.5. Evaluation of radiolabelled peptide degradation 
(7.5 mg/ml creatine phosphate and 1 mg/ml creatine 
kinase), 1 mM IBMX, 0.1 mM PMSF, 1 mg/ml baci- 
tracin, 1 mM EDTA, and test substances (10 -4 M SS or 
10 -5 M FK) in 0.1 ml of 0.025 M triethanolamine/HCl 
buffer (pH 7.4). After a 15 min incubation at 30°C, the 
reaction was stopped by heating the mixture for 3 min. 
After cooling, 0.2 ml of an alumina slurry (0.75 g/ml  in 
triethanolamine/HCl buffer, pH 7.4) was added and the 
suspension was centrifuged. The supernatant was taken for 
assay of cyclic AMP (cAMP) by the method of Gilman 
[13]. The SS concentration used was that necessary to 
achieve inhibition of rat [44] and human [5,12] brain AC 
activity. FK was used at a concentration that could effec- 
tively stimulate the catalytic subunit of rat AC [44]. 
2.7. Data analysis 
The computer program LIGAND [25] was used to 
analyze the binding data. The use of this program enabled 
models of receptors that best fit the given sets of data to be 
selected. The same program was also used to present he 
data in the form of Scatchard plots and to compute values 
for receptor affinity (K d) and density (Bma x) that best fit 
the sets of binding data for each rat. Statistical compar- 
isons of all the data were carried out with one way analysis 
of variance (ANOVA) and the Student Newman-Keuls 
test. Means among groups were considered significantly 
different when the P value was less than 0.05. Each 
individual experiment was performed in duplicate. 
3. Results 
As shown in Table 1, SS-mediated inhibition of basal 
and FK-stimulated AC activity was markedly increased in 
The inactivation of [125I]TyrH-SS in the incubation 
medium after exposure to membranes was studied by 
measuring the ability of preincubated peptide to rebind to 
fresh membranes [1]. Briefly, [125 I]Tyr1LSS (250 pM) was 
incubated with membranes from rat hippocampus (0.15 mg 
protein/ml) for 60 rain at 30°C. After this preincubation, 
aliquots of the medium were added to fresh membranes 
and incubated for an additional 60 min at 30°C. The 
fraction of the added radiolabelled peptide which was 
specifically bound during the second incubation was mea- 
sured and expressed as a percentage of the binding that 
had been obtained in control experiments performed in the 
absence of membranes during the preincubation period. 
2.6. Adenylyl cyclase assay 
AC activity was measured as previously reported [17] 
with minor modifications. Briefly, hippocampal mem- 
branes (0.06 mg/ml) were incubated with 1.5 mM ATP, 5 
mM MgSO4, 10 p.M GTP, an ATP-regenerating system 
Table 1 
Effect of somatostatin (SS) (10 -4 M) and forskolin (FK) (10 -5 M) on 
brain adenylyl cyclase activity (pmol cAMP/min /mg protein) in hip- 
pocampal membranes from control rats (n = 15) and rats treated with 0.1 
/,tg (n = 5), 1.0 /zg (n = 5) or 10.0 /,tg (n = 5) of histamine 
Control Histamine 
0.1 ~,g 1.0 ~g 10 jzg 
Basal activity 119+4 123+1 118+10 121+2 
.-t-10 -4 MSS 995-4 1005-3 97_+4 93_+2 
% SS inhibition of 17 + 1 19 _+ 2 18 ± 1 23 5- 1 " ° 
basal activity 
+10 -3 MFK 6345-16 6825-51 606+11 631±38 
Fold FK stimulation 5.2:1:0.3 5.5 -+ 0.3 5.1 + 0.2 5.4 ± 0.3 
over basal 
+10 -5 MFK+ 488:t:11 487-1-26 4785-6 398+13 
10 -4 M SS 
% SS inhibition of 23±1 28+3 21±3 37-1-2 " ' "  
FK stimulation 
Values represent he mean5-SEM of five separate experiments, each 
performed in duplicate. In the control group, the results express the mean 
value of a pool of the control animals. Statistical comparison versus 
control: " " P < 0.01, " " " P < 0.001. 
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l'ablc 2 
Effect of somatostatin (11) : M) and torskolin (1(1 ' M) ~,n brain 
adenylatc yclasc activity (pmol/cAMP/min/mg protein) in hippocam- 
pal membranes from control rats (n = 10) and rats pretrcatcd with 
mepyraminc (30 mg/kg, i.p.) (n=5)  or cimetidinc (20 ,ug, i.c.v.) 
(n = 5) 1 h before histamine (10 #g. i.c.v.)injection 
Control Mepyraminc Cimctidinc 
plus histamine plus histamine 
Basal activity 120+.3 125 5-b 124+.7 
+10 a MSS 101±2 97L4 95!3  
% SS inhibition of 16+1 225-2 "" 23+3 ' 
basal activity 
~" l0 -s M FK 636 f32 h4(l+2h b53 _~23 
+.1(I -s MFKt  489+_28 422+34 424 L 31 
ll) -4 M SS 
f4 SS inhibition of 23 ~ 3 34 ± 4 " 35 + 5 " 
FK stimulation 
Value,,, represent he mean_+ SEM ol five separate experiments, each 
perfl)rmcd in duplicate. In the control group, the results express the mean 
value of a pool of the control animals. Statistical comparison versus 
control: t' < 0.05. " " I' < O.Ol. 
hippocampal membranes from rats treated with 10.0 /.tg of 
histamine as compared with control rats. The response of 
AC to the diterpene forskolin (FK), which is assumed to 
act directly upon the catalytic subunit of AC, was also 
examined. The results obtained indicate that the ability of 
the diterpene to stimulate the enzyme activity was not 
altered after histamine administration. In addition, no sig- 
nificant differences were observed for the basal and FK- 
stimulated AC activities between control and histamine- 
treated (0.1, 1.0 or l(I.0 /xg) rats (Table 1). Pretreatment 
with the histamine H~ or H: receptor antagonists mepyra- 
mine and cimetidine, respectively, also induced an increase 
in SS-mediated inhibition of basal and FK-stimulated AC 
activity (Tablc 2). 
Hippocampal G, function, as assessed by inhibiting FK 
(3 × 10 ~' M)-stimulated AC activity with the stable GTP 
analog Gpp[NH]p, was similar in control and histamine (10 
/,~g)-treated rats (Fig. 1). 
Preliminary experiments confirmed that the specific 
binding of [~-~51]Tyrll-SS to hippocampal membranes 
changed linearly with protein concentration and was time- 
dependent in all experimental groups. An apparent equilib- 
rium was observed between 50 and 18(1 min at 30°C (data 
not shown). All subsequent binding expcriments were 
therefore conducted at 30°C for 60 min. Hippocampal 
membranes from all experimental groups showed a similar 
peptide degradation capacity and the values varied by no 
more than 10% among the groups. 
SS binding to hippocampal membranes was found to be 
markedly increased after histamine administration at a 
dose of 10.0 /xg as compared with controls (Fig. 2). This 
increase was due to a rise in the maximal number of SS 
receptors (48.2%), as revealed by Scatchard plots of the 
binding data (Table 3: Fig. 2). In addition, a significant 
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mediated inhibition of adenylyl cyclasc (AC) activity in rat hippocampal 
membranes from control (O) (n -  5) and histamine (10.() /xg)-treated 
( O ) ( n :- 5) rats. Curves for the action of Gpp[NH]p on AC activity wcrc 
carried out in the presence of 3× 10 -¢' M forskolin (FK) and the 
indicated concentrations of Gpp{NH]p. Data arc expressed as a percentage 
~f FK-stimulated AC activity in the absence of Gpp[NH]p (100g;). The 
results are given as the mean _- SEM of five separate determinations, each 
pcrh)rmed in duplicate. No statistically significant differences were ob- 
tained between the control and histamine-treated rats. 
decrease in the affinity of these receptors (39%) was 
observed (Table 3, Fig. 2). No changes in the number or 
affinity of the SS receptors were detected at the lower 
doses of 0.1 or 1.0 /,Lg of histamine (Table 3). The 
addition of 10 5 M histamine to the incubation medium 
changed neither the number nor the affinity of the SS 
receptors in hippocampal membranes from normal rats 
(data not shown). With the aim of determining if the 
changes in SS binding were related to histamine binding to 
its specific receptor sites, the histamine H t and H~ recep- 
t0.0 o 
t- 
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5.0 
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Fig. 2. Effect of histamine (tO.0 gg, i.c.v.) on somatostatin (SS) binding 
to rat hippocampal membranes. Left panel: Competitive inhibition of 
',pecific [lZSllTyrtI-SS binding by unlabelled SS to hippocampal mem- 
branes. Membranes (0.15 mg protcin/ml) were incubated for 60 min at 
3I)'C in the presence of 250 pM [neSl]'l'yrl~-SS and increasing concentra- 
tions of native peptidc. Points corres[xmd to values for the control rats 
(O) (n = 5) and rats treated with 10.0 tzg of histamine ((3) (n = 5). Each 
point represents he mean + SEM of five experiments, each performed in 
duplicate. Right panel: Scatchard analysis of the binding data. 
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Table 3 
Effect of increasing concentrations of histamine (0.1 /.tg, 1.0 /zg or 10.0 
p,g) and of pretreatment with cimetidine (20 /~g/rat) plus mepyramine 
(30 mg/kg)  administered 1 h before histamine (10.0 p,g) on equilibrium 
parameters for somatostatin (SS) binding to rat hippocampal membranes 
and on SS-like immunoreactivity (SSLI) concentration i  the rat hip- 
pocampus 
Group SS receptors SSLI n 
Bmax Ko 
Control 393+15 0.32+0.03 16.14+1.81 5 
Histamine 0.1 /~g 428± 16 0.30±0.03 15.46±2.09 5 
Control 408-1-14 0.38+0.03 13.08+2.19 5 
Histamine 1.0/zg 418±26 0.34+0.04 14.21+0.60 5 
Control 365 -1- 16 0.41 ± 0.03 11.06 ± 1.27 5 
Histamine 10.0 p,g 541+24 ° ° " 0.57+0.04 ' 12.59+0.86 5 
Binding parameters were calculated from Scatchard plots by linear regres- 
sion. Units for SSLI are ng of SS per mg of protein, units for K d are nM 
and units for Bma x are fmol of SS bound per mg of protein. The results 
are represented as the mean + SEM of five separate xperiments, each 
performed in duplicate. Statistical comparison versus control: " P < 0.05, 
• ' "  P < 0.001. 
tor antagonists mepyramine and cimetidine, respectively, 
were administered 1 h before histamine administration. A 
29.5% and 27.2% increase in the number of SS receptors 
accompanied by a 69.6% and 72.7% decrease in their 
apparent affinity was observed in rats pretreated with 
mepyramine or cimetidine, respectively (Table 4). The 
pretreatment with mepyramine and cimetidine adminis- 
tered simultaneously prevented the histamine-induced 
changes in SS binding to its receptors (Table 4). 
The i.c.v, administration of histamine at a dose of 0.1, 
1.0 or 10.0/xg did not significantly affect SSLI content in 
the hippocampus as compared with the control groups 
(Table 3). 
Table 4 
Effect of pretreatment with mepyramine (30 mg/kg,  i.p.), cimetidine (20 
~g, i.c.v.) or mepyramine plus cimetidine administered 1 h before 
histamine (10 pg, i.c.v.) injection on equilibrium parameters for somato- 
statin (SS) binding to rat hippocampal membranes 
Group SS receptors n 
Brnax Kd 
Control 389+ 13 0.33+0.04 15 
Mepyramine plus histamine 504 ± 20 ' 0.56 :[: 0.04 ° 5 
Cimetidine plus histamine 495 :t: 23 " 0.57 ± 0.04 " 5 
Mepyramine plus cimetidine 395 ± 21 0.33 + 0.01 5 
plus histamine 
Binding parameters were calculated from Scatchard plots by linear regres- 
sion. Units for K d are nM and units for B®8 x are fmol of SS bound per 
mg of protein. The results are represented as the mean ± SEM of five 
separate xperiments, each performed in duplicate. In the control group, 
the results express the mean value of a pool of the controls (n = 15), 
since the Bmx and K d values were not affected by the vehicle. Statistical 
comparison versus control: " P < 0.05. 
4. Discussion 
This study demonstrates for the first time that the 
number of SS receptors and the AC response to SS are 
increased in the hippocampus of rats treated with 10.0 /.tg 
of histamine, an effect hat is mediated by both H 1 and H 2 
histaminergic receptors. The hippocampus was chosen to 
examine the modulation of the SS receptor/effector sys- 
tem due to the high concentration of SS and its receptors 
[21,40] in spite of the moderate density of histaminergic 
fibers [33,53] present in this brain area. This moderate 
density of histaminergic fibers may explain the fact that 
changes in the somatostatinergic system were only ob- 
served at the highest dose tested. 
The increased capacity of SS to inhibit basal and FK- 
stimulated AC activity in rats treated with 10.0 /zg of 
histamine, as compared with the control group, is most 
likely related to the observed rise in the number of SS 
receptors. Indeed, the basal and FK-stimulated enzyme 
activities are not altered by histamine, suggesting that the 
catalytic subunit of AC is not involved in the increased 
response to SS. Furthermore, the functional activity of the 
G i protein was similar in the control and histamine (10.0 
/xg)-treated group, which suggests that there is no abnor- 
mality in the coupling of the SS receptor to AC. 
A relatively high concentration of SS (10 -4 M) was 
required to produce inhibition of AC activity. This same 
SS concentration was used by Schettini et al. [44], 
Bergstr6m et al. [5] and Garlind et al. [12] in their studies 
on SS-mediated inhibition of AC activity in the rat and 
human brain. This concentration is three log units higher 
than that necessary to displace [125I]Tyr1~-SS binding. A 
possible explanation for this discrepancy may lie in the 
observation that G-proteins can modulate the affinity of SS 
receptors and/or the coupling to the effector system (AC 
among others). In this respect, Enjalbert et al. [9] and Koch 
and Schonbrunn [20] have demonstrated that the mobiliza- 
tion of the G-protein by GTP reduces the SS receptor 
affinity for the neuropeptide in cerebral cortical cells and 
GH4C ~ pituitary cell clones. Indeed, in the presence of 
GTP necessary to couple the SS receptor to the AC 
catalytic subunit, the SS receptor may shift from an appar- 
ent high-affinity state (observed in binding studies) to an 
apparent low-affinity state (observed in AC studies). 
The SSLI content and the equilibrium parameters of the 
SS receptors in the hippocampus of control rats were 
similar to those previously reported by others [36,47]. 
Scatchard analysis of the stoichiometric data suggests the 
existence of only one type of SS receptor. This finding 
agrees with some studies in rat brain membranes in which 
[125I]Tyrlt-SS was also used as a tracer [10,47] but differs 
from other reported ata where different SS analogs were 
used [38,48]. Recently, five different SS receptor subtypes 
have been cloned [4] and the tissue distribution of the 
messenger ribonucleic acid for each subtype has been 
studied in the rat [6,35]. The fact that this study with 
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[125I]Tyr~-SS shows only one type of SS receptor might 
be explained by the hypothesis that this radioligand binds 
to all types of SS receptors with dissociation constants that 
are virtually identical and cannot be discriminated by 
Scatchard analysis. 
Overall, the present data are suggestive of a possible 
role of histamine as a modulator of the SS receptor/effec- 
tor system in the hippocampus. The molecular mechanism 
underlying the increase in SS receptors and SS-mediated 
AC inhibition in hippocampal membranes of histamine 
(10.0 /xg)-treated rats is unknown. This effect, however, 
seems to be due to a direct interaction of histamine with 
histaminergic receptors which are present in high density 
in this brain area [31,42] since the changes induced by this 
biogenic amine were prevented by pretreatment with the 
histamine H~ and H, receptor antagonists administered 
simultaneously. In addition, blockade of the histamine H~ 
or H e receptors by pretreatment with mepyramine or 
cimetidine, respectively, induced an increase in the number 
of SS receptors and in SS-mediated inhibition of AC 
activity, indicating that both postsynaptic histaminergic 
receptors, H t and H 2, are implicated in the histamine 
effects on the hippocampal somatostatinergic system ob- 
served in this study. The increase in tracer binding was not 
due to a direct effect of histamine on SS receptors ince no 
change in [12Sl]Tyr~l-SS binding was detected following 
incubation of fresh hippocampal membranes with his- 
tamine. The dose response concentration of histamine elic- 
iting an increase in the specific binding of SS in the 
hippocampus is in good agreement with effective doses of 
histamine which have been shown to produce a physio- 
logical effect [41]. Examples of positive control mecha- 
nisms of receptor-receptor interactions include insulin acti- 
vation of the IGF-II receptor [30], thyrotropin-releasing 
hormone activation of SS binding [45] and relaxin activa- 
tion of [ 125 l]Tyr l l_insulin binding [29]. 
The role of SS receptors in the hippocampus, a structure 
involved in the regulation of behavior, especially cognitive 
functions [55], still remains to be elucidated. However, 
there are several lines of evidence suggesting that SS can 
play a physiological role in the modulation of this limbic 
structure [54]. Since the hippocampus receives histaminer- 
gic innervation [33,53] and SS receptors are modulated by 
histamine, it is tempting to speculate that in the hippocam- 
pus, SS could be involved as a mediator of the effects of 
histamine on behaviors such as learning and memory. The 
importance of this observation for basic science and clini- 
cal research requires further exploration. 
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